Get the Stockscreener App
0.6676
1.81%
-0.0123
After Hours:
.67
0.0024
+0.36%
Vyne Therapeutics Inc stock is traded at $0.6676, with a volume of 85,406.
It is down -1.81% in the last 24 hours and up +1.75% over the past month.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions. The company is also in the pre-clinical stages of research, develop and commercialize products containing small molecule bromodomain and extra-terminal domain (BET) inhibitors for the treatment of any disease, disorder or condition in human. Its products include AMZEEQ, ZILXI, and FCD105.
See More
Previous Close:
$0.6799
Open:
$0.6845
24h Volume:
85,406
Relative Volume:
0.53
Market Cap:
$22.29M
Revenue:
$454.00K
Net Income/Loss:
$-21.72M
P/E Ratio:
-1.2509
EPS:
-0.5337
Net Cash Flow:
$-25.74M
1W Performance:
+3.10%
1M Performance:
+1.75%
6M Performance:
+20.59%
1Y Performance:
-53.15%
1-Day Range:
$0.6513
$0.6845
1-Week Range:
$0.647
$0.6949
52-Week Range:
$0.2805
$1.595
Vyne Therapeutics Inc Stock (VYNE) Company Profile
Name
Vyne Therapeutics Inc
Sector
Industry
Phone
800-775-7936
Address
685 ROUTE 202/206 N., SUITE 301, BRIDGEWATER
Compare VYNE vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VYNE
Vyne Therapeutics Inc
|
0.6676 | 21.72M | 454.00K | -21.72M | -25.74M | -0.5337 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vyne Therapeutics Inc Stock (VYNE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-31-25 | Downgrade | BTIG Research | Buy → Neutral |
| Nov-18-24 | Initiated | BTIG Research | Buy |
| Dec-06-21 | Resumed | H.C. Wainwright | Buy |
Vyne Therapeutics Inc Stock (VYNE) Latest News
Price to book forward of VYNE Therapeutics Inc. – NASDAQ:VYNE - TradingView
Price to earnings forward of VYNE Therapeutics Inc. – NASDAQ:VYNE - TradingView
Price to sales forward of VYNE Therapeutics Inc. – NASDAQ:VYNE - TradingView
Enterprise value to EBITDA forward of VYNE Therapeutics Inc. – NASDAQ:VYNE - TradingView
VYNE Therapeutics Inc Actuals & Estimates (NASDAQ:VYNE) - TradingView
VYNE Therapeutics Inc Actuals & Estimates (BOATS:VYNE) - TradingView
Vyne Therapeutics Inc (VYNE) Institutional Confidence - TradingKey
VYNE Therapeutics StockSunday background on a micro-cap dermatology player - AD HOC NEWS
Vyne Therapeutics Inc (VYNE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Vyne Therapeutics Inc (VYNE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Vyne Therapeutics Inc (VYNE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Vyne Therapeutics Inc (VYNE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Vyne Therapeutics Inc (VYNE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Vyne Therapeutics Inc (VYNE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Vyne Therapeutics Inc (VYNE) Valuation: PE, PB & Fair Value Analysis - TradingKey
Vyne Therapeutics Inc (VYNE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
[EFFECT] VYNE Therapeutics Inc. SEC Filing - Stock Titan
VYNE (VYNE) merger with Yarrow: $100M financing, 35.8441 exchange ratio - Stock Titan
Zhang Xiaofan discloses 1.87M shares (5.6%) in VYNE Therapeutics (VYNE) - Stock Titan
VYNE Q1 2026 Earnings: EPS Beat Estimate, No Revenue ReportedFinancial Summary - newsline.com
VYNE Therapeutics (VYNE) Edges Higher in Quiet Trading, Testing Key Resistance at $0.69New Listing Stocks - newsline.com
VYNE Therapeutics (VYNE) Consolidates Near Support After Slight PullbackMACD Signal Stocks - newsline.com
[Form 4] VYNE Therapeutics Inc. Insider Trading Activity - Stock Titan
VYNE Therapeutics (VYNE) Posts Modest Gain, Holds Above Key SupportMotive Wave - newsline.com
VYNE Therapeutics (VYNE) Edges Lower as Shares Test Key Support Near $0.65Standard Deviation - thelegaladvocate.com
RKTO Stock Price and Chart — NASDAQ:RKTO - TradingView
VYNE Highlights Yarrow Merger Strategy and Endocrine Pipeline - TipRanks
VYNE to Advance YB-101 into Phase 2 in Q2 2026; $200M Raised, Phase 2a Readout Expected H2 2027 - TradingView
Yarrow reverse merger refocuses VYNE (NASDAQ: VYNE) with $200M war chest - Stock Titan
VYNE Therapeutics (VYNE) price target decreased by 38.46% to 2.04 - MSN
VYNE SEC FilingsVyne Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Nantahala (NASDAQ: VYNE) reports 2,000,000-share stake representing 6.00% - Stock Titan
Yarrow merger to refocus VYNE (NASDAQ: VYNE) with $200M financing - Stock Titan
MSN Money - MSN
TradingKey - TradingKey
Vyne Therapeutics Inc expected to post a loss of 18 cents a shareEarnings Preview - TradingView
The regulatory exposure in VYNE Therapeutics (VYNE) results | Q4 2025: Earnings Beat EstimatesNon-GAAP Earnings - The Legal Advocate
VYNE Therapeutics (NASDAQ: VYNE) to become Yarrow Bioscience after merger - Stock Titan
VYNE Therapeutics Inc. (VYNE) beats Q4 2025 EPS expectations significantly, yet shares edge slightly lower in today's trading.Special Dividend - UBND thành phố Hải Phòng
VYNE Therapeutics Inc. (VYNE) reports narrower Q4 2025 loss than estimates, yet shares dip slightly in today’s trading.Post Announcement - Xã Vĩnh Công
Vyne Therapeutics Inc Stock (VYNE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):